Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.
about
HDAC inhibitors and immunotherapy; a double edged sword?The Mcm2-7 replicative helicase: a promising chemotherapeutic targetQuercetin enhances the antitumor activity of trichostatin A through upregulation of p53 protein expression in vitro and in vivoIntegrating genomics and proteomics data to predict drug effects using binary linear programming2-Benzazolyl-4-Piperazin-1-Ylsulfonylbenzenecarbohydroxamic Acids as Novel Selective Histone Deacetylase-6 Inhibitors with Antiproliferative ActivityHistones and lung cancer: Are the histone deacetylases a promising therapeutic target?A combined approach for the study of histone deacetylase inhibitors.L-carnitine is an endogenous HDAC inhibitor selectively inhibiting cancer cell growth in vivo and in vitro.Ginsenoside Rg3 inhibits melanoma cell proliferation through down-regulation of histone deacetylase 3 (HDAC3) and increase of p53 acetylation.Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity.MicroRNA-222 regulates MMP-13 via targeting HDAC-4 during osteoarthritis pathogenesis.Silibinin synergizes with histone deacetylase and DNA methyltransferase inhibitors in upregulating E-cadherin expression together with inhibition of migration and invasion of human non-small cell lung cancer cells.Mechanisms of trichostatin A inhibiting AGS proliferation and identification of lysine-acetylated proteinsSimultaneously defining cell phenotypes, cell cycle, and chromatin modifications at single-cell resolution.Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistanceHDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses.Histone deacetylase inhibitors modulate miRNA and mRNA expression, block metaphase, and induce apoptosis in inflammatory breast cancer cellsSuberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4(+) T cells.Decreased expression of connective tissue growth factor in non-small cell lung cancer is associated with clinicopathological variables and can be restored by epigenetic modifiers.Overexpression screens identify conserved dosage chromosome instability genes in yeast and human cancerA novel histone deacetylase inhibitor, CKD5, has potent anti-cancer effects in glioblastoma.Targeting class I histone deacetylases in cancer therapy.Epigenetics and oncology.Epigenetic alternations and cancer chemotherapy response.Epigenetic alterations of gastrokine 1 gene expression in gastric cancer.A quinazoline-based HDAC inhibitor affects gene expression pathways involved in cholesterol biosynthesis and mevalonate in prostate cancer cells.Inhibitors of enzymes catalyzing modifications to histone lysine residues: structure, function and activity.A Subset of Nuclear Receptors are Uniquely Expressed in Uveal Melanoma Cells.Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and AzacytidineCooperation of histone deacetylase inhibitors SAHA and valproic acid in promoting sodium/iodide symporter expression and function in rat Leydig testicular carcinoma cells.Class II-specific histone deacetylase inhibitors MC1568 and MC1575 suppress IL-8 expression in human melanoma cells.Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells.Sulforaphane Reverses the Expression of Various Tumor Suppressor Genes by Targeting DNMT3B and HDAC1 in Human Cervical Cancer Cells.Human skin permeation of emerging mycotoxins (beauvericin and enniatins).Combination of palladium nanoparticles and tubastatin-A potentiates apoptosis in human breast cancer cells: a novel therapeutic approach for cancer.[Epigenetic regulation in sepsis : current state of knowledge].Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitorsNovel biomolecule lycopene-reduced graphene oxide-silver nanoparticle enhances apoptotic potential of trichostatin A in human ovarian cancer cells (SKOV3).Treponema denticola increases MMP-2 expression and activation in the periodontium via reversible DNA and histone modifications.Depletion of HDAC1, 7 and 8 by Histone Deacetylase Inhibition Confers Elimination of Pancreatic Cancer Stem Cells in Combination with Gemcitabine.
P2860
Q26853102-9E6F7C8D-2C8D-4069-9E2D-391A80F4017FQ26861045-1152B5E6-F5BD-4D12-A665-F6A50081E4E7Q28485136-B8DCC057-E57B-40A7-BC97-BC6393A2FE68Q28540932-80556AD5-00E6-4DB2-9079-BF0EA048DBE6Q28551721-5FD5582B-A64E-4AD3-B7FB-76017B554984Q34371189-934E74FB-24F6-492B-A434-CCCD07AAC4CDQ34390285-21762E09-BA76-439A-B595-FD113283D8EEQ34472177-6A146673-E14B-4B72-9F83-4C4C2AC61F3DQ34734168-F01B2DBB-9398-45EF-AEE1-40FAA8992208Q36109506-CF89521E-907C-42A7-A535-D784235BD6CCQ36323810-03C27098-534A-442F-A91B-0D56E3CE7A25Q36776566-3C47ED42-8AFE-47DC-8338-2F5FFDC692ACQ36897907-3172E85F-63B9-4C48-90D7-44F12559444EQ36945123-3F227B83-7173-4C34-B4D3-762BBFAC1FA6Q37021699-23DA9930-1B11-4990-9512-EDE6413BC722Q37073624-842C8BE5-C531-404A-9B82-AEFDD0064D4BQ37092688-BD0E7365-9583-456D-ACE5-1982649391CCQ37119662-03BF8676-7D15-4492-A920-4E6ECE7861FAQ37162642-42634854-5F0F-4D7D-A589-86ECC11A21B5Q37247500-7EC94C55-492F-4500-BFFA-5929BB71B803Q37705920-43316EF4-1E83-427E-8FAC-77210240ED07Q38051736-B306DD1F-5F44-4843-8241-99D569C5CCD1Q38195260-B7EF4F17-E5D8-418D-8281-6E6D176CF174Q38680431-DD793411-15A7-499B-981A-0CCBD9E78B44Q38719120-C3FA8596-DFF5-494E-A981-71B695BAE427Q38804294-DBDEE1E9-B081-40A9-B9E1-F651B36D3703Q38833038-FFB5326F-2ECC-429F-AE49-F2F262213EA3Q38848709-47251B0C-EEF9-4F94-9A3D-645845DD25E8Q38881033-8831C145-B81D-41E6-A4D7-A82D5E0A9A25Q39157582-262D30E1-D5A7-4B38-944C-7FEB179D0B73Q39240051-74C3A3BC-3299-447F-A94E-8A036043759AQ39281746-B0AE6D1D-DF19-4447-830F-0B8672B27F92Q40751870-0E2E4B89-0B2B-4044-B8AB-27AA2A478923Q41252565-3550B244-27F8-4239-B97E-879D23142BC5Q41382946-B1AF66CD-A1C0-4358-BFFF-EC7C651EC10FQ41620454-3987C64B-9ABD-43E5-9C4C-1F9EE91B054AQ42555454-82C825CF-2D87-4EF5-8CC7-F4DC6454293FQ42659391-3FDD106A-AF4A-4319-9568-E09BB6EEDC94Q46021184-17C5E852-642D-4B2C-B195-260229B972C2Q48157879-37C70C98-574A-48A3-9C89-C3629F653EA2
P2860
Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.
@en
Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.
@nl
type
label
Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.
@en
Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.
@nl
prefLabel
Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.
@en
Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.
@nl
P2093
P2860
P356
P1476
Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.
@en
P2093
D S Varghese
E D Martinez
M C Gillam
R L Schiltz
P2860
P2888
P304
P356
10.1038/BJC.2011.532
P407
P577
2011-12-08T00:00:00Z